StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Avalo Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$68.29M. For fiscal 2025 it was -$51.46M. The highest annual figure on record is $12.58M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.46M–
FY2024Dec 31, 2024-$49.06M–
FY2023Dec 31, 2023-$30.68M–
FY2022Dec 31, 2022-$26.75M–
FY2021Dec 31, 2021-$70.89M–
FY2020Dec 31, 2020-$40.54M–
FY2019Dec 31, 2019-$19.13M–
FY2018Dec 31, 2018-$3.13M-124.9%
FY2017Dec 31, 2017$12.58M–
FY2016Dec 31, 2016-$14.57M–
FY2015Dec 31, 2015-$10.16M–
FY2014Dec 31, 2014-$15.52M–
FY2013Dec 31, 2013-$11.49M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.99M–
Q1 FY2026Mar 31, 2026-$17.69M–
Q4 FY2025Dec 31, 2025-$14.25M–
Q3 FY2025Sep 30, 2025-$16.37M–
Q2 FY2025Jun 30, 2025-$11.39M–
Q1 FY2025Mar 31, 2025-$9.46M–
Q4 FY2024Dec 31, 2024-$15.04M–
Q3 FY2024Sep 30, 2024-$11.53M–
Q2 FY2024Jun 30, 2024-$16.28M–
Q1 FY2024Mar 31, 2024-$6.20M–
Q4 FY2023Dec 31, 2023-$2.77M–
Q3 FY2023Sep 30, 2023-$6.84M-219.4%
Q2 FY2023Jun 30, 2023-$11.03M–
Q1 FY2023Mar 31, 2023-$10.05M–
Q4 FY2022Dec 31, 2022-$3.94M–
Q3 FY2022Sep 30, 2022$5.73M–
Q2 FY2022Jun 30, 2022-$12.47M–
Q1 FY2022Mar 31, 2022-$16.07M–
Q4 FY2021Dec 31, 2021-$17.10M–
Q3 FY2021Sep 30, 2021-$16.29M–
Q2 FY2021Jun 30, 2021-$19.19M–
Q1 FY2021Mar 31, 2021-$18.32M–
Q4 FY2020Dec 31, 2020-$14.38M–
Q3 FY2020Sep 30, 2020-$11.87M–
Q2 FY2020Jun 30, 2020-$8.56M–
Q1 FY2020Mar 31, 2020-$5.74M–
Q4 FY2019Dec 31, 2019-$1.68M–
Q3 FY2019Sep 30, 2019-$7.62M–
Q2 FY2019Jun 30, 2019-$6.72M–
Q1 FY2019Mar 31, 2019-$3.12M–
Q4 FY2018Dec 31, 2018-$1.98M–
Q3 FY2018Sep 30, 2018-$538.35K-102.8%
Q2 FY2018Jun 30, 2018-$333.67K–
Q1 FY2018Mar 31, 2018-$280.42K–
Q4 FY2017Dec 31, 2017-$2.55M–
Q3 FY2017Sep 30, 2017$19.12M–
Q2 FY2017Jun 30, 2017-$1.76M–
Q1 FY2017Mar 31, 2017-$2.24M–
Q4 FY2016Dec 31, 2016-$3.71M–
Q3 FY2016Sep 30, 2016-$3.43M–

More Avalo Therapeutics figures

See a number that looks wrong?